Fetal muscle gene transfer is not enhanced by an RGD capsid modification to high-capacity adenoviral vectors

被引:17
|
作者
Bilbao, R
Reay, DP
Hughes, T
Biermann, V
Volpers, C
Goldberg, L
Bergelson, J
Kochanek, S
Clemens, PR
机构
[1] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA
[2] Univ Cologne, Ctr Mol Med, Cologne, Germany
[3] Childrens Hosp Philadelphia, Div Infect Dis & Immunol, Philadelphia, PA 19104 USA
[4] Dept Vet Affairs Med Ctr, Neurol Serv, Pittsburgh, PA USA
关键词
in utero; high-capacity adenoviral vector; muscle; RGD; targeting;
D O I
10.1038/sj.gt.3302084
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
High levels of alpha(v) integrin expression by fetal muscle suggested that vector re-targeting to integrins could enhance adenoviral vector-mediated transduction, thereby increasing safety and efficacy of muscle gene transfer in utero. High-capacity adenoviral (HC-Ad) vectors modified by an Arg-Gly-Asp (RGD) peptide motif in the HI loop of the adenoviral fiber (RGD-HC-Ad) have demonstrated efficient gene transfer through binding to alpha(v) integrins. To test integrin targeting of HC-Ad vectors for fetal muscle gene transfer, we compared unmodified and RGD-modified HC-Ad vectors. In vivo, unmodified HC-Ad vector transduced fetal mouse muscle with four-fold higher efficiency compared to RGD-HC-Ad vector. Confirming that the difference was due to muscle cell autonomous factors and not mechanical barriers, transduction of primary myogenic cells isolated from murine fetal muscle in vitro demonstrated a three-fold better transduction by HC-Ad vector than by RGD-HC-Ad vector. We hypothesized that the high expression level of coxsackievirus and adenovirus receptor (CAR), demonstrated in fetal muscle cells both in vitro and in vivo, was the crucial variable influencing the relative transduction efficiencies of HC-Ad and RGD-HC-Ad vectors. To explore this further, we studied transduction by HC-Ad and RGD-HC-Ad vectors in paired cell lines that expressed alpha(v) integrins and differed only by the presence or absence of CAR expression. The results increase our understanding of factors that will be important for retargeting HC-Ad vectors to enhance gene transfer to fetal muscle.
引用
收藏
页码:1821 / 1829
页数:9
相关论文
共 50 条
  • [41] Cloning and Large-Scale Production of High-Capacity Adenoviral Vectors Based on the Human Adenovirus Type 5
    Ehrke-Schulz, Eric
    Zhang, Wenli
    Schiwon, Maren
    Bergmann, Thorsten
    Solanki, Manish
    Liu, Jing
    Boehme, Philip
    Leitner, Theo
    Ehrhardt, Anja
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2016, (107):
  • [42] High-capacity adenovirus/lentivirus hybrid vectors for efficient and stable gene transfer via a two-stage mechanism
    Kubo, S
    Faure, E
    Soifer, H
    Jih, LJL
    Ngiam, C
    Barcova, M
    Kim, JH
    Stripecke, R
    Cannon, P
    Kasahara, N
    CANCER GENE THERAPY, 2004, 11 (12) : 854 - 854
  • [43] Systemic delivery of a high-capacity adenoviral vector expressing mouse CTLA4Ig improves skeletal muscle gene therapy
    Jiang, ZL
    Feingold, E
    Kochanek, S
    Clemens, PR
    MOLECULAR THERAPY, 2002, 6 (03) : 369 - 376
  • [44] Immune response to full-length dystrophin delivered to Dmd muscle by a high-capacity adenoviral vector
    Gilchrist, SC
    Ontell, MP
    Kochanek, S
    Clemens, PR
    MOLECULAR THERAPY, 2002, 6 (03) : 359 - 368
  • [45] Delivery of CRISPR/Cas9 or TALENs Against Hepatitis B Virus cccDNA by High-Capacity Adenoviral Vectors
    Schiwon, Maren
    Bergmann, Thorsten
    Ehrke-Schulz, Eric
    Ehrhardt, Anja
    MOLECULAR THERAPY, 2016, 24 : S9 - S9
  • [46] Induction of long-term immune tolerance for neo-antigens following gene therapy with high-capacity adenoviral vectors by transient elimination of Kupffer cells
    VandenDriessche, T
    Schiedner, G
    Thorrez, L
    Brown, B
    Johnston, M
    Gillijns, V
    Hertel, S
    Van Rooijen, N
    Collen, D
    Chuah, L
    Kochanek, S
    Lillicrap, D
    MOLECULAR THERAPY, 2003, 7 (05) : S193 - S193
  • [47] One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: Clinical implications
    Barcia, Carlos
    Jimenez-Dalmaroni, Maximiliano
    Kroeger, Kurt M.
    Puntel, Mariana
    Rapaport, Alison J.
    Larocque, Daniel
    King, Gwendalyn D.
    Johnson, Stephen A.
    Liu, Chunyan
    Xiong, Weidong
    Candolfi, Marianela
    Mondkar, Sonali
    Ng, Philip
    Palmer, Donna
    Castro, Maria G.
    Lowenstein, Pedro R.
    MOLECULAR THERAPY, 2007, 15 (12) : 2154 - 2163
  • [48] INVIVO GENE-TRANSFER TO THE LIVER USING ADENOVIRAL VECTORS RESULTS IN HIGH TRANSFECTION EFFICIENCY
    DRAZAN, KE
    WU, L
    BULLINGTON, D
    JURIM, O
    GRAHAM, F
    BERK, A
    BUSUTTIL, RW
    SHAKED, A
    GASTROENTEROLOGY, 1993, 104 (04) : A897 - A897
  • [49] Genetic Manipulation of High-Capacity Adenoviral Vectors Utilizing Bacterial Artificial Chromosomes and Rapid Small-Scale Vector Preparations
    Hausl, Martin
    Rauschhuber, Christina
    Voigtlander, Richard
    Ruzsics, Zsolt
    Ehrhardt, Anja
    HUMAN GENE THERAPY, 2010, 21 (09) : 1196 - 1196
  • [50] A genetically modified adenoviral vector exhibits enhanced gene transfer of human smooth muscle cells
    Su, EMJ
    Stevenson, SC
    Rollence, M
    Marshall-Neff, J
    Liau, G
    JOURNAL OF VASCULAR RESEARCH, 2001, 38 (05) : 471 - 478